JP2025516264A5 - - Google Patents

Info

Publication number
JP2025516264A5
JP2025516264A5 JP2024564522A JP2024564522A JP2025516264A5 JP 2025516264 A5 JP2025516264 A5 JP 2025516264A5 JP 2024564522 A JP2024564522 A JP 2024564522A JP 2024564522 A JP2024564522 A JP 2024564522A JP 2025516264 A5 JP2025516264 A5 JP 2025516264A5
Authority
JP
Japan
Prior art keywords
hla
item
items
cells
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024564522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516264A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/020338 external-priority patent/WO2023215183A1/en
Publication of JP2025516264A publication Critical patent/JP2025516264A/ja
Publication of JP2025516264A5 publication Critical patent/JP2025516264A5/ja
Pending legal-status Critical Current

Links

JP2024564522A 2022-05-02 2023-04-28 多重化t細胞受容体組成物、その併用療法、及び使用 Pending JP2025516264A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263337522P 2022-05-02 2022-05-02
US63/337,522 2022-05-02
US202263342451P 2022-05-16 2022-05-16
US63/342,451 2022-05-16
US202263413553P 2022-10-05 2022-10-05
US63/413,553 2022-10-05
US202263423269P 2022-11-07 2022-11-07
US63/423,269 2022-11-07
PCT/US2023/020338 WO2023215183A1 (en) 2022-05-02 2023-04-28 Multiplexed t cell receptor compositions, combination therapies, and uses thereof

Publications (2)

Publication Number Publication Date
JP2025516264A JP2025516264A (ja) 2025-05-27
JP2025516264A5 true JP2025516264A5 (cg-RX-API-DMAC7.html) 2026-05-13

Family

ID=88646870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024564522A Pending JP2025516264A (ja) 2022-05-02 2023-04-28 多重化t細胞受容体組成物、その併用療法、及び使用

Country Status (12)

Country Link
US (1) US20250288675A1 (cg-RX-API-DMAC7.html)
EP (1) EP4519305A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025516264A (cg-RX-API-DMAC7.html)
KR (1) KR20250006149A (cg-RX-API-DMAC7.html)
CN (1) CN119487060A (cg-RX-API-DMAC7.html)
AU (1) AU2023265422A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248253A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024016274A2 (cg-RX-API-DMAC7.html)
IL (1) IL316250A (cg-RX-API-DMAC7.html)
MX (1) MX2024013482A (cg-RX-API-DMAC7.html)
TW (1) TW202406569A (cg-RX-API-DMAC7.html)
WO (1) WO2023215183A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024005746A (es) * 2021-11-10 2024-07-19 Tscan Therapeutics Inc Peptidos inmunogenicos magea1, proteinas de union que reconocen peptidos inmunogenicos magea1, y usos de estos.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113595A2 (en) * 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
NZ741124A (en) * 2012-07-27 2019-11-29 Univ Illinois Engineering t-cell receptors
JP6895975B2 (ja) * 2016-01-06 2021-06-30 ヘルス リサーチ インコーポレイテッドHealth Research, Inc. 組換えt細胞受容体を含む組成物及びライブラリー並びに組換えt細胞受容体を使用する方法
KR20190062505A (ko) * 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
JP7289028B2 (ja) * 2018-09-05 2023-06-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 複数の主要組織適合遺伝子複合体分子に制限したny-eso-1-特異的t細胞受容体の組成物
WO2020167957A1 (en) * 2019-02-12 2020-08-20 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
DE102019121007A1 (de) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
EP4010377A4 (en) * 2019-08-09 2023-09-06 A2 Biotherapeutics, Inc. CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS

Similar Documents

Publication Publication Date Title
JP7770188B2 (ja) 養子細胞療法のための標的共刺激を提供する受容体
AU2015230741B9 (en) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
JP5563194B2 (ja) 改変t細胞レセプターを発現する細胞
JP2024517618A5 (cg-RX-API-DMAC7.html)
US20060135418A1 (en) Receptors
TW201828977A (zh) 新穎t細胞受體以及使用彼之免疫療法
KR20190016507A (ko) TGFβRII의 프레임시프트 돌연변이체를 인식하는 T-세포 수용체
US12365717B2 (en) Specific t cell receptors against epitopes of mutant MYD88L265P protein for adoptive T cell therapy
CN114502580B (zh) Mhc ii类分子及其使用方法
JP2023549765A5 (cg-RX-API-DMAC7.html)
EP3898665B1 (en) Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
JP2024515646A5 (cg-RX-API-DMAC7.html)
JP2022546106A (ja) Ebv-由来抗原に特異的なtcr構築物
TW202118780A (zh) Ii類mhc分子及其使用方法
TW202406569A (zh) 多重t細胞受體組合物、組合療法及其用途
Shimizu et al. Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells
JP2022554349A5 (cg-RX-API-DMAC7.html)
Savage Cancer immunotherapy therapeutic manipulation of the CD8-HLA class I interaction: potential and challenges
Subklewe Current status of immunotherapy in acute myeloid leukemia
EP4577562A1 (en) Immunotherapeutics based on magea1-derived epitopes
WO2024243807A1 (zh) 靶向ny-eso-1的高亲和力t细胞受体及其应用
JP2025541260A (ja) T細胞受容体
TW202602496A (zh) 抗ha-1及抗ha-2結合蛋白用於治療aml、all及mds之用途
HK40065284A (en) Receptors providing targeted costimulation for adoptive cell therapy
HK40065284B (en) Receptors providing targeted costimulation for adoptive cell therapy